Merus and Halozyme have signed a worldwide non-exclusive partnership and licence agreement for subcutaneous formulation of petosemtamab.
The agreement involves the development and commercialisation of the administration of petosemtamab, an epidermal growth factor receptor (EGFR) times leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) bispecific antibody, using Enhanze drug delivery technology.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Merus licensed Halozyme’s Enhanze technology to accelerate advancement for the subcutaneous administration.
Halozyme will receive an upfront fee, additional payments linked to commercial milestones and sales success from Meru, and low to mid single-digit royalties on net sales of petosemtamab formulated with the technology during the royalty period.
Merus chief operating officer and general counsel Peter Silverman stated: “Petosemtamab continues to show encouraging results in the clinical studies across numerous solid tumour cancers and has the potential to become a first and best in class treatment in head and neck cancer and beyond.
“We are proud to collaborate with Halozyme and look forward to working closely with their team on a subcutaneous administration.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHalozyme president and CEO Dr Helen Torley stated: “We are excited to collaborate with Merus to advance treatment options for patients with r/m HNSCC and other potential indications.
“This collaboration represents a new opportunity for our Enhanze technology to improve treatment efficiency and enhance the patient treatment experience. Together, we aim to accelerate innovation for patients and healthcare providers.”
Halozyme owns the enzyme rHuPH20 which underpins Enhanze, a solution enabling rapid subcutaneous drug delivery to lessen the treatment burden on patients.
The Enhanze technology has been licensed by companies including Takeda, Roche, Janssen, Pfizer and AbbVie.
In September 2025, Genmab signed an agreement to buy all shares of Merus at $97 per share, in an all-cash transaction valued at $8bn, boosting its oncology pipeline.
